Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Effect and safety of high-dose dienogest (20 mg/day) in the treatment of women with endometriosis

Schindler, Adolf E., Henkel, Alexandra, Moore, Claudia, Oettel, Michael · 2010 · Archives of Gynecology and Obstetrics

Abstract

Purpose Hormonal treatment of endometriosis is often continued for long periods and has the potential to affect many essential metabolic processes. The current study aimed to determine the effects and safety of high-dose dienogest as a medical endometriosis therapy.Methods The effects and safety of high-dose dienogest, 20-30 mg/day for 24 weeks, were examined in 21 women aged 18-52 years with laparoscopically and histologically proven endometriosis stage I-IV (according to revised American Society of Reproductive Medicine criteria). At baseline and week 24, sera were obtained and stored at -20°C prior to analysis.Results The study showed no clinically significant effect of high-dose dienogest on thyroid or adrenal function, electrolyte balance or haematopoiesis. High-dose dienogest therapy also had no appreciable effects on glucose and lipid metabolism, liver enzymes or haemostasis. For instance, although dienogest mediated small increases in the haemostatic variables prothrombin fragment 1 + 2, antithrombin III and protein C, final levels (at week 24) remained within normal reference ranges for these parameters. The exception was the HDL-3 cholesterol concentration at week 24 (0.97 mmol/l), which increased beyond the normal range of 0.28-0.64 mmol/l.Conclusions This investigation yielded a unique dataset on the safety of high-dose dienogest in endometriosis stage I-IV. High-dose dienogest (20-30 mg/day) had little influence upon all the parameters measured. It is therefore likely that lower doses of dienogest would have similarly neutral safety effects: an important consideration in the use of dienogest for the treatment of endometriosis.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00404-009-1301-z

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 2

  1. Oettel M, Carol W, Elger W (1995) A 19-norprogestin without 17β-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 31:517–536
  2. Momoeda M, Taketani Y (2007) Randomized double-blind, multicentre, parallel-group dose–response study of dienogest in patients with endometriosis. Jpn Pharmacol Ther 35:769–783

Cited by

See all 38

Metadata

Authors
Schindler, A. E., Henkel, A., Moore, C., & Oettel, M.
Affiliations
  • University of Duisburg-Essen (DE)
  • St.-Johannes-Hospital Dortmund (DE)
Corresponding author
Schindler, Adolf E.
Venue
Archives of Gynecology and Obstetrics
Published
2009-12-15
Volume
282
Issue
5
Pages
507-514
ISSN
  • 0003-9128 (ISSN-L)
  • 0932-0067
  • 1432-0711
OpenAlex
W2023365171
Cited by
36
References
30
Citations by year
2025: 1 · 2022: 1 · 2021: 1 · 2020: 4 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 5 · 2013: 4 · 2012: 4
FWCI
4.71
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Archives of Gynecology and Obstetrics (publishedVersion)
  • PubMed (publishedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
dienogest, endometriosis, drug safety, hemostasis, prothrombin fragment 1+2, antithrombin III, protein C, thyroid function, adrenal function, electrolyte balance, glycolipid metabolism, liver enzymes
MeSH terms
Adolescent, Adult, Antithrombin III, Cholesterol, Dose-Response Relationship, Drug, Endometriosis, Female, Hormone Antagonists, Humans, Middle Aged, Nandrolone, Peptide Fragments, Pilot Projects, Protein C, Prothrombin, Surveys and Questionnaires, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect and safety of high-dose dienogest (20 mg/day) in the treatment of women with endometriosis. https://app.cochat.ai/papers/10.1007/s00404-009-1301-z
The paper
Schindler, A. E., Henkel, A., Moore, C., & Oettel, M. (2010). Effect and safety of high-dose dienogest (20 mg/day) in the treatment of women with endometriosis. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-009-1301-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.